Patent for dengue treatment

Dengue fever is a severe viral disease spread by vectors. The viruses responsible for dengue fever are known as arboviruses. Currently, dengue fever mainly affects countries in South and Southeast Asia, Africa, Oceania, and the Caribbean. Each year, between 50 and 528 million people contract the disease, resulting in approximately 10,000 to 20,000 deaths.

«Serum Institute of India Pvt. Ltd.» has obtained a Eurasian patent (No. 046342) for a live attenuated flavivirus vaccine composition. This patent pertains to an immunogenic composition comprising one or more live attenuated dengue viruses comprising a plurality of live attenuated dengue (DEN) viruses of different serotypes selected from a group consisting of DEN-1, DEN-2, DEN-3 and DEN-4, in which the dengue virus is present at a dose of 2.5 — 3.0 log 10 PFU per 0.5 ml and excipients. The composition preserves desired characteristics of the virus, including virus viability, immunogenicity and stability.

The suggested vaccine compositions are proven to be effective in treating and preventing dengue infections, as well as preventing, ameliorating or delaying the onset or progression of the clinical manifestations thereof.

«Serum Institute of India Pvt. Ltd.» is currently recognized as the largest vaccine manufacturer globally, with over 1.3 billion doses produced and distributed worldwide, including vaccines for Polio, Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps, and Rubella.